You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物(603392.SH):全資子公司通過GMP符合性檢查
格隆匯 06-04 15:43

格隆匯6月4日丨萬泰生物(603392.SH)公佈,2025年6月4日,福建省藥品監督管理局網站公示,資子公司廈門萬泰滄海生物技術有限公司《藥品生產質量管理規範》符合性檢查結果。本次獲批的九價HPV疫苗是公司自主研發的預防用生物製品,覆蓋HPV16/18/31/33/45/52/58七種高危型和HPV6/11兩種低危型,可預防上述型別人乳頭瘤病毒感染引起的相關疾病。

此前全球範圍內僅有一款九價 HPV 疫苗上市,為默沙東的佳達修®9。佳達修®9 於 2018 年在中國獲批。根據默沙東佳達修®9 國內代理商重慶智飛生物製品股份有限公司公開年報數據顯示,2024年,默沙東的佳達修®9的批簽發量約3,114萬劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account